Subetta is a new drug currently under review for approval by the FDA and undergoing phase 3 clinical trials. By activating insulin receptors, Subetta has an antihyperglycemic effect, stimulating uptake of glucose by muscle cells. The trials suggest Subetta has a small but statistically significant additional blood glucose-lowering effect in people whose type 1 diabetes is not effectively managed with basal bolus insulin regimens, and it does not seem to increase the risk of adverse events like hypoglycemia. Read more